Eye Health News and Research

Latest Eye Health News and Research

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, today announced the release of Therapeutic Area Essentials™, a comprehensive suite of more than 155 therapeutic area e-courses covering diagnosis, cause, and treatment for over 40 disease states.

9 Mar 2010

Clinical and scientific advances made in the field of neuro-oncology

Many important clinical and basic scientific advances have been made in the past five years in the field of neuro-oncology, according to an editorial and several articles in the March issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Some anti-depressant drugs are associated with an increased chance of developing cataracts, according to a new statistical study by researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University.

9 Mar 2010

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

Sunridge International, said it will be presenting details of its patented pneumatic trabeculoplasty treatment a non-invasive treatment at the upcoming Southwest Investment Association, Inc. Conference on March 13, 2010, at the Westin Stonebriar Hotel in Frisco, Texas.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.

8 Mar 2010

Muscle Flex to develop direct response television infomercial business

Muscle Flex Inc. announced today that it will develop its direct response television infomercial business exclusively under its health and fitness brand, Muscle Flex. Muscle Flex will become a “grittier” and “edgier” health and fitness brand within the company (BRAVADA International Ltd) that will be marketed to a demographic pre-disposed to an aggressive health and fitness lifestyle.

8 Mar 2010

Engineers develop Active Handrest device to help people perform precision tasks with hands

University of Utah engineers developed a computer-controlled, motorized hand and arm support that will let doctors, artists and others precisely control scalpels, brushes and tools over a wider area than otherwise possible, and with less fatigue.

8 Mar 2010

World through the eyes of a person with eye disease

Lighthouse International, the non-profit leader in vision healthcare, research, education and advocacy, launches a new website that features the first customizable, low-vision simulator that shows how a person with an eye disease sees the world. Visitors can choose a video from YouTube and select a filter that simulates retinitis pigmentosa, macular degeneration, glaucoma or diabetic retinopathy.

6 Mar 2010

Obama seeks to mollify Democrats on health overhaul plan, costs

President Barack Obama intensified his push for health care reform by lobbying small groups of Democratic lawmakers Thursday.

5 Mar 2010

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called CYTOMIMIC™ Technology, is a proprietary, patented technology that combines essential minerals to deliver biological levels of electric signals similar to the skin's natural bioelectricity.

5 Mar 2010

Crowding essentially 'blends' nearby objects together and makes the world appear more regular

As you read this, you may notice that the word directly in front of you is clear, but all the surrounding words are hard to make out. For most people, this effect - known as 'crowding' - is not a problem. However, for the millions of people worldwide who have lost their central vision through eye disease such as macular degeneration, it can make everyday tasks such as reading or recognising friends a challenge.

5 Mar 2010

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.

5 Mar 2010

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

According to estimates from the American Cancer Society, melanoma, the most serious form of skin cancer, was responsible for an estimated 8,650 deaths in the United States in 2009. Of growing concern among dermatologists is the fact that melanoma is now the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old.

5 Mar 2010

Natural Solutions offers information about thyroid disease and thyroid medications

Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.

5 Mar 2010

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

If simply the thought of bedbugs, scabies and head lice makes you feel a little itchy, imagine how those affected by these common infestations feel when they learn what has been creeping around them and causing symptoms such as intense itching, red bite marks or irritated scalps.

5 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Gene therapy for LCA clears another hurdle: Study

Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle. The same research team that conducted the human trial now reports that a study in animals has shown that a second injection of genes into the opposite, previously untreated eye is safe and effective, with no signs of interference from unwanted immune reactions following the earlier injection.

4 Mar 2010

Eye Health News and Research

Latest Eye Health News and Research

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Clinical and scientific advances made in the field of neuro-oncology

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Sunridge International to present patented, 2-minute, non-invasive PNT treatment at SWIA Conference

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Muscle Flex to develop direct response television infomercial business

Engineers develop Active Handrest device to help people perform precision tasks with hands

World through the eyes of a person with eye disease

Obama seeks to mollify Democrats on health overhaul plan, costs

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Crowding essentially 'blends' nearby objects together and makes the world appear more regular

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

Natural Solutions offers information about thyroid disease and thyroid medications

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Gene therapy for LCA clears another hurdle: Study

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in